Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III booster vaccination study of HB-AS02V versus HBVAXPRO in dialysis and pre-dialysis patients with loss of hepatitis B antibodies
2005-004059-37Phase 3Completed
- Sponsor
- Henogen
- Start
- Nov 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatitis B (HBV) comparing HB-AS02V booster with HBVAXPRO booster (2 arms). Primary endpoint: Superiority in immunogenicity. Started Nov 2005; status: completed.
02
Drugs
adjuvanted hepatitis B vaccine HB-AS02VRecombivax HB
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2005-004059-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004059-37.